Understanding the VRd Regimen for Newly Diagnosed Myeloma

The VRd regimen combines three drug classes used to treat myeloma: the proteasome inhibitor Velcade®, the immunomodulatory agent Revlimid®, and the steroid dexamethasone. Each drug has a different way of attacking myeloma, and each enhances the activity of the other drugs in this combination. VRd also serves as the backbone of two FDA-approved 4-drug regimens that are currently considered to be the best available therapies for patients with newly diagnosed myeloma: DVRd and Isa-VRd.